Education And Debate

Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading

BMJ 1999; 318 doi: http://dx.doi.org/10.1136/bmj.318.7197.1548 (Published 05 June 1999) Cite this as: BMJ 1999;318:1548
  1. Liam Smeeth, research fellowa,
  2. Andy Haines, professor of primary carea,
  3. Shah Ebrahim, professor of epidemiology and ageing (shah.ebrahim@bristol.ac.uk)b
  1. aDepartment of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, London NW3 2PF
  2. bMRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol BS8 2PR
  1. Correspondence to: Professor Ebrahim
  • Accepted 10 February 1999

The number needed to treat—the number of patients who must be treated to prevent one adverse outcome—is a widely used measure. 1 2 It is increasingly being calculated by pooling absolute risk differences in trials included in meta-analyses. 3 4 This option is available in statistical software and the Cochrane Database of Systematic Reviews. 5 6 In this paper, we examine pooled numbers needed to treat derived from trials and meta-analyses of interventions to prevent cardiovascular disease. We show that a pooled number needed to treat may be misleading because of variation in the event rates in trials, differences in the outcomes considered, effects of secular trends on disease risk, and differences in clinical setting. The number needed to treat should be derived by applying the relative risk reductions from treatment which have been estimated by trials or meta-analysis to relevant baseline risks for different types of patients. This provides a range of possible numbers needed to treat in different patient groups.

Summary points

Numbers needed to treat are often used to summarise treatment effects in a clinically relevant way

They are derived from the baseline risk without treatment and the reduction in risk achieved with treatment

Numbers needed to treat are sensitive to factors that change the baseline risk such as the outcome considered, patients' characteristics, secular trends in incidence and case fatality, and the clinical setting

Pooled numbers needed to treat derived from meta-analyses can be seriously misleading because the baseline risk often varies appreciably between the trials

Applying the pooled relative risk reductions calculated from meta-analyses or individual trials to the baseline risk relevant to specific patient group produces a useful number needed to treat

Methods

The interventions selected for study were use of statins for lowering cholesterol concentrations in primary and secondary prevention of coronary heart disease.7 …

Sign in

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe